ArticleJTCVS open2026
Ten-year outcomes of pulmonary endarterectomy in Switzerland: The Zurich experience.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pulmonary endarterectomy (PEA) is the gold standard for operable chronic thromboembolic pulmonary hypertension (CTEPH), an often underdiagnosed and undertreated disease. Before 2015, Swiss patients had limited access to PEA and were operated abroad, highlighting the need for a CTEPH center in Switzerland despite its small population. We herein summarize our 10-year PEA experience, its influence on patient outcomes, and analyze potential prognosticators for complications and long-term outcomes. Methods: Prospectively collected records of patients with CTEPH undergoing PEA at our institution (January 2015-December 2024) were retrospectively analyzed for perioperative and long-term outcome parameters, prognosticators for complications, and hemodynamic improvement. A benchmark analysis compared our center's results with the International CTEPH Registry. Results: Our cohort included 141 patients with CTEPH undergoing PEA, with 85 (60.3%) male patients and a median age of 62 years (range, 51-71 years). We observed significant improvements in mean pulmonary arterial pressure (mean difference, 16.6 mm Hg; Conclusions: Establishing a PEA program in Switzerland enabled timely, gold standard care for patients with CTEPH. Despite being a small-volume program, outcomes were comparable with high-volume centers. N-terminal pro B-type natriuretic peptide, Jamieson IV, and initial hemodynamic improvements emerged as prognosticators, warranting prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.